SYSTEMIC SCLEROSIS

This study tests whether anifrolumab, an injected drug, can improve symptoms of systemic sclerosis (scleroderma) better than a placebo. About 314 adults aged 18-70 with early-stage disease (less than 6 years) will participate. The main goal is to see if the drug helps skin thicke…

This study tests whether baricitinib, an oral drug, can reduce skin hardening in people with systemic sclerosis, a rare autoimmune disease. About 60 adults with early diffuse systemic sclerosis will receive either baricitinib or a placebo for 24 weeks. The main goal is to measure…

This study tests an experimental drug called MT-0551 against a placebo in 80 adults with systemic sclerosis, a disease that causes skin thickening and can affect internal organs. The main goal is to see if the drug reduces skin hardness over 26 weeks. Researchers will also check …

This early-stage study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy faulty B cells. It aims to control active autoimmune diseases like lupus, scleroderma, and Sjögren's syndrome. The main goal is to check safety, but…

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myositis that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, modified to target and destroy fau…

This early-stage study tests a new treatment called KYV-101 for people with systemic sclerosis, a rare autoimmune disease that causes skin and organ hardening. The therapy uses a patient's own modified immune cells to target and destroy faulty B-cells. The main goals are to check…

This early-stage study tests a new treatment for people with severe lupus or scleroderma that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and f…

This study tests a new treatment using specially engineered immune cells (CAR T-cells) from a donor to target and calm the overactive immune system in people with severe lupus or scleroderma. The goal is to see if it is safe and can reduce disease activity. 18 adults who have not…

This study looks at whether the Shingrix vaccine is safe and effective for people with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who have a higher risk of shingles. About 2,000 participants will receive the vaccine or no vaccine, and researchers will moni…

This study tests whether a fecal microbiota transplant (FMT) can safely reduce chronic diarrhea in people with systemic sclerosis, an autoimmune disease. Twenty adults will receive either FMT or a placebo, and researchers will track side effects and symptom changes. The goal is t…

This study looks at whether giving people with inflammatory arthritis extra help—like a list of community resources, a community specialist, or a nurse navigator—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed a…

This study looks at whether artificial intelligence can analyze CT scans of the lungs to predict how systemic sclerosis-associated lung disease will progress. Researchers will review past scans and health records from 1,000 adults with systemic sclerosis. The goal is to find imag…